blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2732290

EP2732290 - DIAGNOSIS OF ALZHEIMER'S DISEASE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  31.03.2017
Database last updated on 12.07.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
The University of Birmingham
Edgbaston Birmingham
West Midlands B15 2TT / GB
[2014/21]
Inventor(s)01 / NAGY, Zsuzsanna
7 Barnsley Road
Birmingham West Midlands B17 8EB / GB
 [2014/21]
Representative(s)Boult Wade Tennant LLP
Salisbury Square House
8 Salisbury Square
London EC4Y 8AP / GB
[N/P]
Former [2014/21]Boult Wade Tennant
Verulam Gardens
70 Gray's Inn Road
London WC1X 8BT / GB
Application number, filing date12738590.416.07.2012
[2016/21]
WO2012GB51693
Priority number, dateGB2011001224615.07.2011         Original published format: GB 201112246
[2014/21]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2013011294
Date:24.01.2013
Language:EN
[2013/04]
Type: A2 Application without search report 
No.:EP2732290
Date:21.05.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 24.01.2013 takes the place of the publication of the European patent application.
[2014/21]
Type: B1 Patent specification 
No.:EP2732290
Date:25.05.2016
Language:EN
[2016/21]
Search report(s)International search report - published on:EP04.04.2013
ClassificationIPC:C12Q1/68, G01N33/68
[2015/17]
CPC:
G01N33/6896 (EP,CN,US); C12Q1/6883 (KR); C12Q1/6827 (US);
G01N33/68 (KR); G01N2333/91215 (EP,CN,US); G01N2800/2821 (EP,CN,US);
G01N2800/50 (EP,CN,US); G01N2800/52 (EP,CN,US) (-)
Former IPC [2014/21]G01N33/68
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/21]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:DIAGNOSE VON MORBUS ALZHEIMER[2014/21]
English:DIAGNOSIS OF ALZHEIMER'S DISEASE[2014/21]
French:DIAGNOSTIC DE LA MALADIE D'ALZHEIMER[2014/21]
Entry into regional phase14.02.2014National basic fee paid 
14.02.2014Designation fee(s) paid 
14.02.2014Examination fee paid 
Examination procedure14.02.2014Examination requested  [2014/21]
02.04.2014Amendment by applicant (claims and/or description)
01.06.2015Communication of intention to grant the patent
19.11.2015Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
13.01.2016Fee for grant paid
13.01.2016Fee for publishing/printing paid
13.01.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  01.06.2015
Opposition(s)28.02.2017No opposition filed within time limit [2017/18]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
13.01.2016Request for further processing filed
13.01.2016Full payment received (date of receipt of payment)
Request granted
27.01.2016Decision despatched
Fees paidRenewal fee
29.07.2014Renewal fee patent year 03
29.07.2015Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU16.07.2012
AL25.05.2016
AT25.05.2016
BE25.05.2016
BG25.05.2016
CY25.05.2016
CZ25.05.2016
DK25.05.2016
EE25.05.2016
ES25.05.2016
FI25.05.2016
HR25.05.2016
IS25.05.2016
IT25.05.2016
LT25.05.2016
LV25.05.2016
MC25.05.2016
MK25.05.2016
NL25.05.2016
PL25.05.2016
RO25.05.2016
RS25.05.2016
SE25.05.2016
SI25.05.2016
SK25.05.2016
SM25.05.2016
TR25.05.2016
IE16.07.2016
LU16.07.2016
CH31.07.2016
LI31.07.2016
MT31.07.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
[2018/46]
Former [2018/45]HU16.07.2012
AT25.05.2016
BE25.05.2016
BG25.05.2016
CY25.05.2016
CZ25.05.2016
DK25.05.2016
EE25.05.2016
ES25.05.2016
FI25.05.2016
HR25.05.2016
IS25.05.2016
IT25.05.2016
LT25.05.2016
LV25.05.2016
MC25.05.2016
MK25.05.2016
NL25.05.2016
PL25.05.2016
RO25.05.2016
RS25.05.2016
SE25.05.2016
SI25.05.2016
SK25.05.2016
SM25.05.2016
TR25.05.2016
IE16.07.2016
LU16.07.2016
CH31.07.2016
LI31.07.2016
MT31.07.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
Former [2018/38]HU16.07.2012
AT25.05.2016
BE25.05.2016
BG25.05.2016
CY25.05.2016
CZ25.05.2016
DK25.05.2016
EE25.05.2016
ES25.05.2016
FI25.05.2016
HR25.05.2016
IS25.05.2016
IT25.05.2016
LT25.05.2016
LV25.05.2016
MC25.05.2016
MK25.05.2016
NL25.05.2016
PL25.05.2016
RO25.05.2016
RS25.05.2016
SE25.05.2016
SI25.05.2016
SK25.05.2016
SM25.05.2016
IE16.07.2016
LU16.07.2016
CH31.07.2016
LI31.07.2016
MT31.07.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
Former [2018/31]HU16.07.2012
AT25.05.2016
BE25.05.2016
CY25.05.2016
CZ25.05.2016
DK25.05.2016
EE25.05.2016
ES25.05.2016
FI25.05.2016
HR25.05.2016
IS25.05.2016
IT25.05.2016
LT25.05.2016
LV25.05.2016
MC25.05.2016
MK25.05.2016
NL25.05.2016
PL25.05.2016
RO25.05.2016
RS25.05.2016
SE25.05.2016
SI25.05.2016
SK25.05.2016
SM25.05.2016
IE16.07.2016
LU16.07.2016
CH31.07.2016
LI31.07.2016
MT31.07.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
Former [2018/28]HU16.07.2012
AT25.05.2016
BE25.05.2016
CY25.05.2016
CZ25.05.2016
DK25.05.2016
EE25.05.2016
ES25.05.2016
FI25.05.2016
HR25.05.2016
IT25.05.2016
LT25.05.2016
LV25.05.2016
MC25.05.2016
MK25.05.2016
NL25.05.2016
PL25.05.2016
RO25.05.2016
RS25.05.2016
SE25.05.2016
SI25.05.2016
SK25.05.2016
SM25.05.2016
IE16.07.2016
LU16.07.2016
CH31.07.2016
LI31.07.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
Former [2017/37]AT25.05.2016
BE25.05.2016
CZ25.05.2016
DK25.05.2016
EE25.05.2016
ES25.05.2016
FI25.05.2016
IT25.05.2016
LT25.05.2016
LV25.05.2016
MC25.05.2016
NL25.05.2016
PL25.05.2016
RO25.05.2016
RS25.05.2016
SE25.05.2016
SI25.05.2016
SK25.05.2016
SM25.05.2016
IE16.07.2016
LU16.07.2016
CH31.07.2016
LI31.07.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
Former [2017/25]AT25.05.2016
BE25.05.2016
CZ25.05.2016
DK25.05.2016
EE25.05.2016
ES25.05.2016
FI25.05.2016
IT25.05.2016
LT25.05.2016
LV25.05.2016
MC25.05.2016
NL25.05.2016
PL25.05.2016
RO25.05.2016
RS25.05.2016
SE25.05.2016
SI25.05.2016
SK25.05.2016
SM25.05.2016
CH31.07.2016
LI31.07.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
Former [2017/22]AT25.05.2016
BE25.05.2016
CZ25.05.2016
DK25.05.2016
EE25.05.2016
ES25.05.2016
FI25.05.2016
IT25.05.2016
LT25.05.2016
LV25.05.2016
MC25.05.2016
NL25.05.2016
PL25.05.2016
RO25.05.2016
RS25.05.2016
SE25.05.2016
SK25.05.2016
SM25.05.2016
CH31.07.2016
LI31.07.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
Former [2017/17]AT25.05.2016
BE25.05.2016
CZ25.05.2016
DK25.05.2016
EE25.05.2016
ES25.05.2016
FI25.05.2016
IT25.05.2016
LT25.05.2016
LV25.05.2016
MC25.05.2016
NL25.05.2016
PL25.05.2016
RO25.05.2016
RS25.05.2016
SE25.05.2016
SK25.05.2016
SM25.05.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
Former [2017/11]AT25.05.2016
BE25.05.2016
CZ25.05.2016
DK25.05.2016
EE25.05.2016
ES25.05.2016
FI25.05.2016
IT25.05.2016
LT25.05.2016
LV25.05.2016
NL25.05.2016
PL25.05.2016
RO25.05.2016
RS25.05.2016
SE25.05.2016
SK25.05.2016
SM25.05.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
Former [2017/10]BE25.05.2016
CZ25.05.2016
DK25.05.2016
EE25.05.2016
ES25.05.2016
FI25.05.2016
IT25.05.2016
LT25.05.2016
LV25.05.2016
NL25.05.2016
PL25.05.2016
RO25.05.2016
RS25.05.2016
SE25.05.2016
SK25.05.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
Former [2017/09]CZ25.05.2016
DK25.05.2016
EE25.05.2016
ES25.05.2016
FI25.05.2016
IT25.05.2016
LT25.05.2016
LV25.05.2016
NL25.05.2016
RO25.05.2016
RS25.05.2016
SE25.05.2016
BE31.07.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
Former [2017/07]DK25.05.2016
ES25.05.2016
FI25.05.2016
IT25.05.2016
LT25.05.2016
LV25.05.2016
NL25.05.2016
RS25.05.2016
SE25.05.2016
BE31.07.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
Former [2017/03]ES25.05.2016
FI25.05.2016
IT25.05.2016
LT25.05.2016
LV25.05.2016
NL25.05.2016
RS25.05.2016
SE25.05.2016
BE31.07.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
Former [2016/52]ES25.05.2016
FI25.05.2016
LT25.05.2016
LV25.05.2016
NL25.05.2016
RS25.05.2016
SE25.05.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
Former [2016/51]ES25.05.2016
FI25.05.2016
LT25.05.2016
LV25.05.2016
NL25.05.2016
RS25.05.2016
NO25.08.2016
GR26.08.2016
PT26.09.2016
Former [2016/50]ES25.05.2016
FI25.05.2016
LT25.05.2016
LV25.05.2016
NL25.05.2016
RS25.05.2016
NO25.08.2016
Former [2016/49]FI25.05.2016
LT25.05.2016
NL25.05.2016
NO25.08.2016
Former [2016/46]LT25.05.2016
NO25.08.2016
Cited inInternational search[AD]WO02073212  (ISIS INNOVATION [GB], et al) [AD] 1-38 * abstract *;
 [A]WO03007925  (ISIS INNOVATION [GB], et al) [A] 1-38 * page 23, paragraph 1 - paragraph 2 * * page 27, paragraph 3 - page 28, paragraph 1 *;
 [A]WO2009105549  (ONCOMETHYLOME SCIENCES SA [BE], et al) [A] 1-38 * abstract *;
 [A]WO2011007155  (UNIV BIRMINGHAM [GB], et al) [A] 1-38 * page 2, paragraph 3 * * page 12, paragraph 4 - page 13, paragraph 1 * * claims 3,6,10 *;
 [A]  - ZHOU X ET AL, "P53-mediated G1/S checkpoint dysfunction in lymphocytes from Alzheimer's disease patients", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 468, no. 3, ISSN 0304-3940, (20100114), pages 320 - 325, (20091113), XP026819934 [A] 1-38 * abstract * * page 324, column 1, paragraph 3 *
 [A]  - BARTOLOME FERNANDO ET AL, "Distinct Regulation of Cell Cycle and Survival in Lymphocytes from Patients with Alzheimer's Disease and Amyotrophic Lateral Sclerosis", vol. 2, no. 4, ISSN 1936-2625, (20090101), pages 390 - 398, INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, E-CENTURY PUBLISHING CORPORATION, US, URL: www.ijcep.com/IJCEP811004, (20081201), XP008156971 [A] 1-38 * abstract *
 [A]  - KRISTOF ARNOLD S ET AL, "LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non- mTOR-dependent mechanisms", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, (20050901), vol. 314, no. 3, doi:10.1124/JPET.105.083550, ISSN 0022-3565, pages 1134 - 1143, XP002443151 [A] 1-38 * abstract *

DOI:   http://dx.doi.org/10.1124/jpet.105.083550
 [A]  - NAGY Z ET AL, "CELL CYCLE KINESIS IN LYMPHOCYTES IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE", NEUROSCIENCE LETTERS, LIMERICK, IE, (20020111), vol. 317, no. 2, doi:10.1016/S0304-3940(01)02442-9, ISSN 0304-3940, pages 81 - 84, XP001106660 [A] 1-38 * abstract * * page 83, paragraph 3 *

DOI:   http://dx.doi.org/10.1016/S0304-3940(01)02442-9
by applicantWO02073212
    - MCKHANN, G. ET AL., NEUROLOGY, (1984), vol. 34, pages 939 - 944
    - FORLENZA ET AL., BMC MEDICINE, (2010), vol. 8, page 89
    - GUSTAW-ROTHENBERG ET AL., BIOMARK. MED., (2010), vol. 4, no. 1, pages 15 - 26
    - NAGY, J. CELL. MOL. MED., (2005), vol. 9, no. 3, pages 531 - 541
    - WINBLAD ET AL., J. INTERN. MED, (2004), vol. 256, pages 240 - 246
    - WARING SC; ROSENBERG RN., "Genome-Wide Association Studies in Alzheimer Disease", ARCH NEUROL, (2008), vol. 65, no. 3, pages 329 - 334
    - CEDAZO-MINGUEZ A., "Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities", J. CELL. MOL. MED., (2007), vol. 11, no. 6, doi:doi:10.1111/j.1582-4934.2007.00130.x, pages 1227 - 1238, XP055253382

DOI:   http://dx.doi.org/10.1111/j.1582-4934.2007.00130.x
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.